A Center for Disease Control and Prevention Advisory Committee did not vote Wednesday on whether to extend the nation’s stagnation on Johnson & Johnson’s COVID-19 vaccine, despite panelists’ arguments to make final recommendations in light of Gambhir There was insufficient data. Rare blood clotting incidents are likely associated with shots.
While the current cease-fire of the CDC is not binding on Johnson & Johnson vaccines, Issued a warning Federal health officials on Tuesday urged that the vaccine be kept suspended only until the panel votes on “updated recommendations” to use the vaccine. In response to the FDA and CDC advisory on stagnation, all states and DC and Puerto Rico have opted to temporarily stop administering this vaccine.
The CDC has not yet set a date for resuming the panel’s discussion on the subject.
The agency’s designated federal officer for the advisory committee was Drs. “Your input today was incredibly helpful in terms of helping inform our work next week,” said Amanda Cohan.
A member of the committee and former top CDC infectious diseases member Drs. Beth Bell said, “To be very clear, I don’t want to vote on this issue today.”
“I don’t think there was enough information to make an evidence-based decision. We wouldn’t have all the information, but I think there are some things we can gather relatively quickly, which will all have to do with the benefit of the risk. Balance, ”added Dr. Bell.
A working group within the panel said a series of options were discussed this week, recommending using the vaccine only for specific groups of people or skipping the shot altogether, but concluded that they More data is needed on these and other possible cases that can be reported.
White House officials have said Johnson & Johnson’s vaccinations were likely to affect the nationwide vaccination campaign “in a very short period of time”, but supplies from Pfizer and Modernism have been sufficient to meet their goals.
Ongoing trials of the single-shot vaccine have been halted in view of the original standstill. The overseas rollout of the vaccine was also interrupted following a recommendation, as well as major programs launched by state and local authorities in the US to use shots to vaccinate hard-to-reach communities.
“We are in a situation where not making a decision is tantamount to making a decision. Any extension of the stay will actually result in the weakest person in the United States, who was the prime candidate for the Johnson & Johnson vaccine. Will remain insecure,” Maine CDC Director Drs. Nirav Shah, president of the Association of State and Territorial Health Offices, told the committee.
Representatives from both Johnson & Johnson, the Food and Drug Administration, and CDC officials made presentations to the committee, which presented a handful of new details on cases known so far.